{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:16Z","timestamp":1789056436401,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.kint.2019.02.042","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T13:04:29Z","timestamp":1554815069000},"page":"572-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging\u00a0evidence"],"prefix":"10.1016","volume":"96","author":[{"given":"Ramy M.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Barsoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Arman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Selamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Hasnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.02.042_bib1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(12)70285-1","article-title":"Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study","volume":"13","author":"Harshman","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2019.02.042_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00280-012-2004-x","article-title":"XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study","volume":"71","author":"Rosati","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.kint.2019.02.042_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1387\/ijdb.103216dr","article-title":"From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials\u2014an interview with Napoleone Ferrara by Domenico Ribatti","volume":"55","author":"Ferrara","year":"2011","journal-title":"Int J Dev Biol"},{"key":"10.1016\/j.kint.2019.02.042_bib5","series-title":"Bevacizumab [FDA package insert]","year":"2004"},{"key":"10.1016\/j.kint.2019.02.042_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Bevacizumab. Oncologist"},{"key":"10.1016\/j.kint.2019.02.042_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4239\/wjd.v7.i16.333","article-title":"Treatment of diabetic retinopathy: recent advances and unresolved challenges","volume":"7","author":"Stewart","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.kint.2019.02.042_bib8","series-title":"Aflibercept [FDA package insert]","year":"2011"},{"key":"10.1016\/j.kint.2019.02.042_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","article-title":"Aflibercept (VEGF trap-eye): the newest anti-VEGF drug","volume":"96","author":"Stewart","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib12","series-title":"Ranibizumab [FDA package insert]","year":"2012"},{"issue":"suppl 1","key":"10.1016\/j.kint.2019.02.042_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0365-6691(12)70046-1","article-title":"[Ranibizumab versus bevacizumab: pharmacological considerations]","volume":"87","author":"Azanza Perea","year":"2012","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib15","unstructured":"Pegaptanib [FDA package insert]. New York, NY: Pfizer Pharmaceuticals; 2004."},{"key":"10.1016\/j.kint.2019.02.042_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","article-title":"Targeting VEGF in eye neovascularization: what\u2019s new? A comprehensive review on current therapies and oligonucleotide-based interventions under development","volume":"103","author":"Amadio","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2019.02.042_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000412","article-title":"Presentation, pathology and prognosis of renal disease in type 2 diabetes","volume":"5","author":"Tan","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.kint.2019.02.042_bib18","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2337\/diab.44.8.968","article-title":"The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial","volume":"44","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2019.02.042_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archopht.122.4.552","article-title":"Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States","volume":"122","author":"Kempen","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ckj\/sfv139","article-title":"Minimal change disease onset observed after bevacizumab administration","volume":"9","author":"Hanna","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2019.02.042_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ckj\/sfy060","article-title":"Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension","volume":"12","author":"Hanna","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2019.02.042_bib22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.042_bib23","first-page":"448","article-title":"Mechanism underlying hypertension and proteinuria caused by bevacizumab","volume":"17","author":"Zeb","year":"2007","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"key":"10.1016\/j.kint.2019.02.042_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.042_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","article-title":"Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?","volume":"45","author":"Al Aly","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.042_bib26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.042_bib27","first-page":"31","article-title":"Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model","volume":"10","author":"Burkhardt","year":"2012","journal-title":"J\u00a0Exp Ther Oncol"},{"key":"10.1016\/j.kint.2019.02.042_bib28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.042_bib29","first-page":"4629","article-title":"Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC","volume":"32","author":"Evans","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.kint.2019.02.042_bib30","first-page":"600","article-title":"[A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab]","volume":"56","author":"Haruhara","year":"2014","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.kint.2019.02.042_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.kint.2019.02.042_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1447-0756.2012.01889.x","article-title":"Exogenous vascular endothelial growth factor supplementation can restore the podocyte barrier-forming capacity disrupted by sera of preeclamptic women","volume":"39","author":"Henao","year":"2013","journal-title":"J\u00a0Obstet Gynaecol Res"},{"key":"10.1016\/j.kint.2019.02.042_bib33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.042_bib34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdq743","article-title":"Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?","volume":"22","author":"Izzedine","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.kint.2019.02.042_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2012.08.037","article-title":"Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function","volume":"151","author":"Jin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.kint.2019.02.042_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.15171\/jnp.2017.23","article-title":"Self-limited membranous nephropathy after intravitreal nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration","volume":"6","author":"Khneizer","year":"2017","journal-title":"J\u00a0Nephropathol"},{"key":"10.1016\/j.kint.2019.02.042_bib37","doi-asserted-by":"crossref","first-page":"F569","DOI":"10.1152\/ajprenal.00180.2012","article-title":"The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response","volume":"303","author":"Kirsch","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.042_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.042_bib39","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2004.09.064","article-title":"Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy","volume":"22","author":"Kumasaka","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2019.02.042_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/annonc\/mdp472","article-title":"Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib","volume":"21","author":"Overkleeft","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.kint.2019.02.042_bib41","first-page":"3465","article-title":"Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab","volume":"27","author":"Pande","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.kint.2019.02.042_bib42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.kint.2019.02.042_bib43","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1111\/ped.12017","article-title":"Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab","volume":"55","author":"Sato","year":"2013","journal-title":"Pediatr Int"},{"key":"10.1016\/j.kint.2019.02.042_bib44","unstructured":"HERCEPTIN (trastuzumab): nouvelle formulation pr\u00eate \u00e0 l'emploi pour administration sous-cutan\u00e9e. Available at: https:\/\/www.vidal.fr\/actualites\/14070\/herceptin_trastuzumab_nouvelle_formulation_prete_a_l_emploi_pour_administration_sous_cutanee\/. Published September 16, 2014. Accessed August 1, 2015."},{"key":"10.1016\/j.kint.2019.02.042_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00408-005-2581-0","article-title":"Acute renal failure associated with gefitinib therapy","volume":"184","author":"Wan","year":"2006","journal-title":"Lung"},{"key":"10.1016\/j.kint.2019.02.042_bib46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nefro.2016.10.011","article-title":"Renal damage associated to intravitreal administration of ranibizumab","volume":"37","author":"Morales","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.kint.2019.02.042_bib47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors","volume":"57","author":"Pelle","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.042_bib48","first-page":"421","article-title":"Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab","volume":"34","author":"Perez-Valdivia","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.kint.2019.02.042_bib49","doi-asserted-by":"crossref","unstructured":"Selamet U, Hanna RM, Rastogi A, Abuddayeh A. Chemotherapeutic agents and the kidney. In: Jaar BG, Ahsan Hejaz A. Renal Protection. Oxford, UK: Oxford University Press; 2018:253\u2013263.","DOI":"10.1093\/med\/9780190611620.003.0026"},{"key":"10.1016\/j.kint.2019.02.042_bib50","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib51","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"suppl 1","key":"10.1016\/j.kint.2019.02.042_bib52","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1136\/bjophthalmol-2013-303844","article-title":"What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.oret.2017.05.015","article-title":"Serum vascular endothelial growth factor levels in the IVAN trial: relationships with drug, dosing, and systemic serious adverse events","volume":"2","author":"Rogers","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.kint.2019.02.042_bib55","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib56","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.ophtha.2018.05.003","article-title":"Re: Jampol et\u00a0al.: Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema (Ophthalmology. 2018;7:1054-1063)","volume":"125","author":"Du","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.kint.2019.02.042_bib57","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/IAE.0000000000002004","article-title":"Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema","volume":"38","author":"Hirano","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.kint.2019.02.042_bib58","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ophtha.2018.01.019","article-title":"Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"125","author":"Jampol","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.kint.2019.02.042_bib59","first-page":"127","article-title":"[Complications of intravitreal injections\u2014own experience]","volume":"113","author":"Jamrozy-Witkowska","year":"2011","journal-title":"Klin Oczna"},{"key":"10.1016\/j.kint.2019.02.042_bib60","first-page":"435","article-title":"Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration","volume":"54","author":"Risimic","year":"2013","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.kint.2019.02.042_bib61","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/eye.2008.360","article-title":"The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension","volume":"23","author":"Rasier","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.kint.2019.02.042_bib62","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/IAE.0b013e3181b21056","article-title":"A\u00a0prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection","volume":"29","author":"Lee","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.kint.2019.02.042_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113701","article-title":"Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys","volume":"9","author":"Tschulakow","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.042_bib64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"Diabetes 2030: insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.kint.2019.02.042_bib65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0889-8529(05)70323-6","article-title":"Diabetic complications: the importance of glucose control","volume":"25","author":"Skyler","year":"1996","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.kint.2019.02.042_bib66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.15171\/ijhpm.2015.06","article-title":"Inadequate control of diabetes and metabolic indices among diabetic patients: a population based study from the Kerman Coronary Artery Disease Risk Study (KERCADRS)","volume":"4","author":"Yousefzadeh","year":"2014","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.kint.2019.02.042_bib67","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","article-title":"Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts","volume":"99","author":"Cheungpasitporn","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2019.02.042_bib68","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A\u00a0phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.kint.2019.02.042_bib69","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1574886309666140211113635","article-title":"Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease\u2014a possible side effect?","volume":"9","author":"Georgalas","year":"2014","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.kint.2019.02.042_bib70","article-title":"Worsening proteinuria following intravitreal anti-VEGF therapy for diabetic macular edema","volume":"10","author":"Kenworthy","year":"2018","journal-title":"J\u00a0Vitreo-Retinal Dis"},{"key":"10.1016\/j.kint.2019.02.042_bib71","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/jdi.12771","article-title":"Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease","volume":"9","author":"Kameda","year":"2018","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.kint.2019.02.042_bib72","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1167\/iovs.17-22853","article-title":"Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema","volume":"59","author":"Glassman","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.kint.2019.02.042_bib73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12886-017-0586-0","article-title":"Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration","volume":"17","author":"Hanhart","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib74","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00417-018-3917-9","article-title":"Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis","volume":"256","author":"Hanhart","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib75","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1111\/aos.13731","article-title":"Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections","volume":"96","author":"Hanhart","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.kint.2019.02.042_bib76","author":"Dalvin"},{"key":"10.1016\/j.kint.2019.02.042_bib77","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.31661\/gmj.v7i0.1299","article-title":"Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational study","volume":"7","author":"Bagheri","year":"2018","journal-title":"Galen Medical Journal"},{"key":"10.1016\/j.kint.2019.02.042_bib78","first-page":"CD011230","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","volume":"9","author":"Moja","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2019.02.042_bib79","first-page":"8637138","article-title":"Classification and differential diagnosis of diabetic nephropathy","volume":"2017","author":"Qi","year":"2017","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.kint.2019.02.042_bib80","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.042_bib81","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2337\/diacare.26.11.2999","article-title":"Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth","volume":"26","author":"Hillier","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2019.02.042_bib82","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadhani","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819304053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819304053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:53:54Z","timestamp":1758761634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819304053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0085253819304053"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.042","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging\u00a0evidence","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}